AARD
Aardvark Therapeutics Inc

124
Mkt Cap
$77.45M
Volume
225,154.00
52W High
$17.94
52W Low
$3.35
PE Ratio
-1.34
AARD Fundamentals
Price
$3.55
Prev Close
$3.51
Open
$3.44
50D MA
$9.95
Beta
1.51
Avg. Volume
120,078.39
EPS (Annual)
-$2.64
P/B
0.73
Rev/Employee
$0.00
$176.74
Loading...
Loading...
News
all
press releases
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Sees Significant Drop in Short Interest
Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) was the recipient of a significant decline in short interest during the month of March. As of March 13th, there was short interest totaling...
MarketBeat·17h ago
News Placeholder
More News
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·3d ago
News Placeholder
BTIG Research Reaffirms Buy Rating for Aardvark Therapeutics (NASDAQ:AARD)
BTIG Research reaffirmed a "buy" rating and set a $9.00 target price on shares of Aardvark Therapeutics in a research note on Tuesday...
MarketBeat·6d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·10d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·17d ago
News Placeholder
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Average Recommendation of "Moderate Buy" from Brokerages
Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the thirteen research firms that are currently covering the firm...
MarketBeat·23d ago
News Placeholder
Oppenheimer Has Lowered Expectations for Aardvark Therapeutics (NASDAQ:AARD) Stock Price
Oppenheimer cut their price target on Aardvark Therapeutics from $35.00 to $21.00 and set an "outperform" rating for the company in a report on Monday...
MarketBeat·27d ago
News Placeholder
AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial
Aardvark Therapeutics shares saw brokerage downgrades after the company paused its Phase 3 trial to treat hyperphagia in patients with Prader-Willi syndrome.
Stocktwits·27d ago
<
...
1
>

Latest AARD News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.